Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wedemeyer, H; Duberg, AS; Buti, M; Rosenberg, WM; Frankova, S; Esmat, G; Örmeci, N; Van Vlierberghe, H; Gschwantler, M; Akarca, U; Aleman, S; Balık, I; Berg, T; Bihl, F; Bilodeau, M; Blasco, AJ; Brandão Mello, CE; Bruggmann, P; Calinas, F; Calleja, JL; Cheinquer, H; Christensen, PB; Clausen, M; Coelho, HS; Cornberg, M; Cramp, ME; Dore, GJ; Doss, W; El-Sayed, MH; Ergör, G; Estes, C; Falconer, K; Félix, J; Ferraz, ML; Ferreira, PR; García-Samaniego, J; Gerstoft, J; Giria, JA; Gonçales, FL; Guimarães Pessôa, M; Hézode, C; Hindman, SJ; Hofer, H; Husa, P; Idilman, R; Kåberg, M; Kaita, KD; Kautz, A; Kaymakoglu, S; Krajden, M; Krarup, H; Laleman, W; Lavanchy, D; Lázaro, P; Marinho, RT; Marotta, P; Mauss, S; Mendes Correa, MC; Moreno, C; Müllhaupt, B; Myers, RP; Nemecek, V; Øvrehus, AL; Parkes, J; Peltekian, KM; Ramji, A; Razavi, H; Reis, N; Roberts, SK; Roudot-Thoraval, F; Ryder, SD; Sarmento-Castro, R; Sarrazin, C; Semela, D; Sherman, M; Shiha, GE; Sperl, J; Stärkel, P; Stauber, RE; Thompson, AJ; Urbanek, P; Van Damme, P; van Thiel, I; Vandijck, D; Vogel, W; Waked, I; Weis, N; Wiegand, J; Yosry, A; Zekry, A; Negro, F; Sievert, W; Gower, E.
Strategies to manage hepatitis C virus (HCV) disease burden.
J Viral Hepat. 2014; 21 Suppl 1(41):60-89
Doi: 10.1111/jvh.12249
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Stauber Rudolf
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical. © 2014 John Wiley & Sons Ltd.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Aged, 80 and over -
- Antiviral Agents - therapeutic use
- Diagnostic Tests, Routine - statistics & numerical data
- Disease Eradication -
- Drug Therapy, Combination - methods
- Female -
- Global Health -
- Hepatitis C, Chronic - diagnosis
- Hepatitis C, Chronic - drug therapy
- Hepatitis C, Chronic - epidemiology
- Humans -
- Incidence -
- Male -
- Middle Aged -
- Models, Statistical -
- Prevalence -
- Young Adult -
- Find related publications in this database (Keywords)
- diagnosis
- epidemiology
- HCV
- mortality
- treatment
- scenarios
- prevalence
- incidence
- hepatitis C
- disease burden